Etoposide

Generic Name
Etoposide
Brand Names
Etopophos, Toposar, Vepesid
Drug Type
Small Molecule
Chemical Formula
C29H32O13
CAS Number
33419-42-0
Unique Ingredient Identifier
6PLQ3CP4P3
Background

A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication

For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
Associated Therapies
-
Clinical Trials
Related News

Combination Chemotherapy Before Surgery in Treating Children With Localized Neuroblastoma

Phase 3
Completed
Conditions
Neuroblastoma
First Posted Date
2003-01-27
Last Posted Date
2013-12-04
Lead Sponsor
Societe Internationale d'Oncologie Pediatrique
Target Recruit Count
100
Registration Number
NCT00025428
Locations
🇩🇰

Odense University Hospital, Odense, Denmark

🇨🇭

Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

🇦🇹

St. Anna Children's Hospital, Vienna, Austria

and more 9 locations

Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma

First Posted Date
2003-01-27
Last Posted Date
2013-12-04
Lead Sponsor
Societe Internationale d'Oncologie Pediatrique
Target Recruit Count
400
Registration Number
NCT00002898
Locations
🇬🇧

Institute of Child Health, Bristol, England, United Kingdom

Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma

First Posted Date
2003-01-27
Last Posted Date
2016-08-10
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
98
Registration Number
NCT00039195
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia

First Posted Date
2003-01-27
Last Posted Date
2014-02-14
Lead Sponsor
Children's Oncology Group
Target Recruit Count
221
Registration Number
NCT00002756
Locations
🇺🇸

Children's Hospital Central California, Madera, California, United States

🇺🇸

Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

🇺🇸

Kaplan Cancer Center at St. Mary's Medical Center, West Palm Beach, Florida, United States

and more 137 locations

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma

First Posted Date
2003-01-27
Last Posted Date
2013-05-17
Lead Sponsor
Children's Oncology Group
Target Recruit Count
495
Registration Number
NCT00004188
Locations
🇺🇸

Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States

🇺🇸

Marshfield Clinic - Marshfield Center, Marshfield, Wisconsin, United States

🇺🇸

Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States

and more 93 locations

Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

First Posted Date
2003-01-27
Last Posted Date
2013-02-28
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
206
Registration Number
NCT00002649
Locations
🇺🇸

Southwest Oncology Group, San Antonio, Texas, United States

Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

First Posted Date
2003-01-27
Last Posted Date
2013-02-27
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
840
Registration Number
NCT00020709
Locations
🇺🇸

Southwest Oncology Group (SWOG) Research Base, San Antonio, Texas, United States

Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

First Posted Date
2003-01-27
Last Posted Date
2013-02-07
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
27
Registration Number
NCT00027898
Locations
🇺🇸

University of Colorado, Denver, Colorado, United States

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma

First Posted Date
2003-01-27
Last Posted Date
2023-06-29
Lead Sponsor
Eastern Cooperative Oncology Group
Target Recruit Count
854
Registration Number
NCT00003389
Locations
🇨🇦

Princess Margaret Hospital, Toronto, Ontario, Canada

🇺🇸

Piedmont Hospital, Atlanta, Georgia, United States

🇺🇸

Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

and more 529 locations

Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma (ALCL 99)

Phase 3
Completed
Conditions
Lymphoma
First Posted Date
2003-01-27
Last Posted Date
2022-05-31
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
885
Registration Number
NCT00006455
Locations
🇫🇷

Institut Gustave Roussy, Villejuif, France

🇦🇹

St. Anna Children's Hospital, Vienna, Austria

🇩🇪

Kinderklinik, Giessen, Germany

and more 7 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy